ACIP Recommendations: COVID-19 Vaccine

Published in Morbidity and Mortality Weekly Report (MMWR)

The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).

CURRENT COVID-19 Vaccine Recommendations

MMWR, December 12, 2024. Vol 73 (49); 1118-1123
Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Print version

MMWR, September 10, 2024. Vol 73 (37);819-824
Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025.
Print version

ARCHIVED COVID-19 Immunization Publications

For your convenience, these archived publications can be used for historical and research purposes.

MMWR, April 25, 2024, Vol 73(16);377-381
Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Print version

MMWR, October 20, 2023, Vol 72(42);1140–1146
Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
Print version

MMWR, June 16, 2023, Vol 72(24);657–662
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
Print version

MMWR, November 11, 2022, Vol 71(45); 1436-1441
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 | MMWR (cdc.gov)
Print version

MMWR, August 4, 2022, Vol 71(31); 988-992
Interim Recommendation of the Advisory Committee on Immunization Practices for use of the Novavax COVID-19 vaccine in persons aged 18 years and older— United States, July 2022
Print version

MMWR, June 28, 2022, Vol 71(26);859–868
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
Print version

MMWR, March 18, 2022, Vol 71(11);416–421
Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
Print version

MMWR, January 21, 2022, Vol 71(3);90–95
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices – United States, December 2021
Print version

MMWR, November 5, 2021, Vol 70(45);1579–1583
Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Print version

MMWR, November 5, 2021, Vol 70(44);1545–1552
Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
Print version

MMWR, September 24, 2021, Vol 70(38);1344–1348
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
Print version

MMWR, August 13, 2021, Vol 70(32);1094-1099
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
Print version

MMWR, July 9, 2021, Vol 70(27);977–982
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Print version

MMWR, May 14, 2021, Vol 70(20);749–752
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
Print version

MMWR, April 30, 2021, Vol 70(17);651-656
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
Print version

MMWR, March 2, 2021, Vol 70(9);329–332
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
Print version

MMWR, December 22, 2020, Vol 69(5152);1657-1660
The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020
Print version

MMWR, December 20, 2020, Vol 69(5152);1653-1656
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
Print version

MMWR, December 13, 2020, Vol 69(50);1922-1924
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
Print version

MMWR, December 3, 2020, Vol 69(49);1857-1859
The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
Print version